Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma

The IO/TKI regimens which combines Immune checkpoint inhibitors (IO) with Tyrosine Kinase Inhibitors (TKI) have become the standard first-line option for advanced ccRCC. Currently, IO/TKI regimens are serving as neoadjuvant treatment in arising clinical trials for ccRCC. Although anatomical change reflected by radiological response is reported in most neoadjuvant trials, only few studies focus on evaluation for pathological response in ccRCC. The TRIPLE-PATH trial is an investigator initiated prospective, open-label phase II trial with the main objective to evaluate the clinical activity of p

Trial Details

NCT ID
NCT07571551
Phase
PHASE2
Sponsor
Jinling Hospital, China
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Toripalimab
  • Lenvatinib
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Patients have fully understood and give written informed consent prior to receive neoadjuvant therapy. Patients with history of major psychiatric d…
  • Patients with the ages range from 18 to 80 years old (at the time of signing informed consent);
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1;
  • Patients have at least 1 measurable target lesion according to RECIST v1.1. The target lesion can be biopsied as per protocol.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →